Your account is not claimed yet. You can sign up with ORCID to claim your account.

Miika Ahdesmäki

Publication Activity (10 Years)

Years Active: 2017-2022
Publications (10 Years): 3

Top Topics

Radical Prostatectomy

Prostate Cancer

Top Venues

Cancer research communications

AstraZeneca plc

Tampereen Teknillinen yliopisto (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

AstraZeneca plc

United Kingdom

Associate Director :: Oncology

Education History

Tampereen Teknillinen yliopisto

Finland

PHD :: Signal Processing

Publications

Kunzah Jamal, Alessandro Galbiati, Joshua Armenia, Giuditta Illuzzi, James A Hall, Sabrina Bentouati, Daniel Barrell, Miika Ahdesmäki, null null, Lenka Oplustil O'Connor, Elisabetta Leo, Josep V Forment
Drug-gene Interaction Screens Coupled to Tumor Data Analyses Identify the Most Clinically Relevant Cancer Vulnerabilities Driving Sensitivity to PARP Inhibition. Cancer research communications 2 (10) (2022)
Kunzah Jamal, Alessandro Galbiati, Joshua Armenia, Giuditta Illuzzi, James A Hall, Sabrina Bentouati, Daniel Barrell, Miika Ahdesmäki, null null, Lenka Oplustil O'Connor, Elisabetta Leo, Josep V Forment
Drug-gene Interaction Screens Coupled to Tumor Data Analyses Identify the Most Clinically Relevant Cancer Vulnerabilities Driving Sensitivity to PARP Inhibition. Cancer research communications 2 (10) (2022)
Gillian Ellison, Miika Ahdesmäki, Sally Luke, Paul M Waring, Andrew Wallace, Ronnie Wright, Benno Röthlisberger, Katja Ludin, Sabine Merkelbach-Bruse, Carina Heydt, Marjolijn J L Ligtenberg, Arjen R Mensenkamp, David Gonzalez de Castro, Thomas Jones, Ana Vivancos, Olga Kondrashova, Patrick Pauwels, Christine Weyn, Eric Hahnen, Jan Hauke, Richie Soong, Zhongwu Lai, Brian Dougherty, T Hedley Carr, Justin Johnson, John Mills, J Carl Barrett
An evaluation of the challenges to developing tumor BRCA1 and BRCA2 testing methodologies for clinical practice. Human mutation 39 (3) (2017)